OBJECTIVES Personalised medicine continues to be a hot topic in healthcare evaluation, particularly in diseases where response to therapy within the patient population is often heterogenous. The results of an analysis previously presented at ISPOR showed that the proportion of cancer trials investigating personalised medicine rose 7-fold between 2000 and 2010. However, in 2011, this trend appeared to have reached a plateau, with the proportion of cancer trials considering personalised medicine settling at around 15-20%. The aim of this study was to update the previous research to take account of the proportion of cancer trials which included personalised medicine between 2012 and 2013, inclusive, to assess whether this pattern has changed in more recent years. METHODS Terms including ‘diagnostic’, ‘prognostic’ and ‘biomarker’ were used to search ClinicalTrials.gov for all interventional cancer trials which started between 2012 and 2013 and considered the use of individualised medicine. These trials were then compared to those of all interventional cancer trials listed on ClinicalTrials.gov starting in the same period. RESULTS Of all cancer trials analysed between 2000 and 2013, inclusive, 3,664 of 25,203 (14.5%) considered personalised medicine. Although the previous analysis showed a substantial increase in this proportion between 2000 and 2010, this trend does not appear to continue into the current decade. The proportion of trials considering personalised medicine identified in this update was consistent with that seen in 2011, with 17.7% of trials in 2012 and 18.8% in 2013 considering personalised medicine, perhaps signifying a lack of further increase in research interest. CONCLUSIONS Surprisingly, in spite of the apparent drive and enthusiasm for the use of personalised medicine within the medical community, these results indicate that the proportion of such trials may have reached a plateau. Therefore, this might suggest that cancer research is continuing to focus on traditional, non-personalised interventions.